Further refinement analysis of correlation between PART1 expression and clinic pathologic characteristics of NSCLC patients showed that among the 60 patients, high expression of PART1 (fold change ≥2.5) comprised 32 persons (Table 1). The gene discussed is PART1; the disease is non-small cell lung carcinoma.